Home

Home

article image

No chance for the next influenza.

Influenza prevention

NICE renewed flu guidance

The next flu season will come. To prevent high-risk people from infections, the National Institute for Health and Clinical Excellence (NICE) recently published a final guidance on the use of the drugs oseltamivir, amantadine and zanamivir for the prophylaxis of influenza. "But vaccination is the main way to prevent flu", says Gillian Leng, NICE Deputy Chief Executive.

NICE guidance recommends oseltamivir and zanamivir for the post-exposure prophylaxis or prevention of ’flu if all of the  following circumstances apply:

During localised outbreaks of ‘flu-like illness guidance recommends oseltamivir and zanamivir be used for people living in long-term residential or nursing homes who have been in contact with the illness, whether or not they are vaccinated. However, this should be done only if there is a high level of certainty that the cause of the localised outbreak is influenza.

This guidance does not cover the circumstances of a pandemic, an impending pandemic, or a widespread epidemic of a new strain of influenza to which there is little or no community resistance. Oseltamivir and zanamivir are not recommended for general use during ‘flu season for prevention of the illness, unless the circumstances above apply. Amantadine is not recommended for the prophylaxis of influenza.

Dr Gillian Leng, NICE Deputy Chief Executive, and Executive Lead for this guidance said: “With the ‘flu season fast approaching, NICE has reviewed and extended it’s guidance on drug treatments for prevention of the illness. Although the majority of people who get ‘flu get better with in 1-2 weeks, some develop more serious problems such as chest infections. People who live in residential accommodation, such as care homes, or who are in other healthcare settings are at greater risk of becoming infected.

“Vaccination is the main way to prevent flu and the Department of Health currently recommends that people who are at risk of ‘flu infection or complications are vaccinated at the beginning of each winter. Oseltamivir and zanamivir can be used as an additional treatment option as they work in a way that stops the virus from multiplying in the body.”

About the guidance

1. The oseltamivir, amantadine and zanamivir for the prophylaxis of influenza guidance is
available at: http://www.nice.org.uk/TA158

2. For the purpose of this guidance, people at risk are defined as those who fall into one or more of the clinical risk groups defined, and updated, each year by the Chief Medical Officer. The current list includes people with:

People who are aged 65 years or older are also defined as at-risk for the purpose of this guidance.

3. Exposure to an influenza-like illness is defined as close contact with a person in the same
household or residential setting who has had recent symptoms of influenza.

4. People who are not effectively protected by vaccination include:

This article was published on 10/02/2008

Search

 

Service

Company News

Technical infrastructure for EU funded R-bay project

Carestream Health is a major technical infrastructure provider to the EU-funded R-Bay validation project, which aims to address the uneven spread of radiologists across member states. CARESTREAM Radiology and Information Management Solutions are driving the initial test platform for the project by facilitating remote reporting of images from hospitals in Denmark, Finland and Czech Republic by clinical providers in Estonia, Lithuania and the Netherlands.

Accu-Chek® Combo – put effective diabetes management into action

At the annual congress of the European Association for the Study of Diabetes (EASD) this year in Rome, Roche Diabetes Care introduced Accu-Chek Combo – the insulin pump system that combines an insulin pump with an intelligent glucose monitoring system, a bolus calculator, and an integrated pump remote-control.

Meet us at MEDICA! Hall 7 Stand 15

The European Hospital team will be happy to hear about your research, products, R&D or trials and launches, hospital management issues, or any other aspects of your work, so that we can discuss your editorial ideas. We will also be pleased to help with any PR or advertising queries.